Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
HEPA Quote, Financials, Valuation and Earnings
Last price:
$0.07
Seasonality move
:
-6.82%
Day range:
$0.06 - $0.07
52-week range:
$0.03 - $36.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.48x
Volume:
45.7K
Avg. volume:
16.9K
1-year change:
-99.71%
Market cap:
$789.7K
Revenue:
--
EPS (TTM):
-$13.40
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Hepion Pharmaceuticals, Inc. has 2084681.1% upside to fair value with a price target of -- per share.
HEPA vs. S&P 500
-
Over the past 5 trading days, Hepion Pharmaceuticals, Inc. has underperformed the S&P 500 by -0.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hepion Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hepion Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hepion Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Hepion Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Hepion Pharmaceuticals, Inc. reported earnings per share of -$0.04.
Enterprise value:
378K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.09x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-230.44%
Net Income Margin (TTM):
--
Return On Equity:
-524.07%
Return On Invested Capital:
-305.96%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$73.3K | -$43K | -- | -- | -- | |
| Operating Income | -$45.9M | -$25.4M | -$4.9M | -$4.5M | -$527.9K | |
| EBITDA | -$45.9M | -$25.3M | -$4.9M | -$4.5M | -$527.9K | |
| Diluted EPS | -$12.51 | -$4.39 | -$13.40 | -$0.72 | -$0.04 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $105.5M | $65.7M | $21.3M | $3.5M | $3.7M | |
| Total Assets | $111.6M | $69.7M | $25M | $3.7M | $3.7M | |
| Current Liabilities | $7.1M | $7.5M | $6.4M | $2.7M | $347.4K | |
| Total Liabilities | $9M | $10.4M | $8.8M | $4.1M | $415.8K | |
| Total Equity | $102.6M | $59.3M | $16.2M | -$406.7K | $3.3M | |
| Total Debt | $99.1K | -- | $129.3K | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$36.7M | -$26.1M | -$4.1M | -$2.5M | -$446K | |
| Cash From Investing | -$30.3K | -$600.3K | -$132.1K | -$600K | -- | |
| Cash From Financing | -$3.1M | $8.8M | $5M | $2.5M | -$157.4K | |
| Free Cash Flow | -$36.7M | -$26.1M | -$4.2M | -$2.5M | -$446K | |
HEPA
Sector
Market Cap
$789.7K
$28.2M
Price % of 52-Week High
0.2%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-1495.85%
-1.54%
1-Year Price Total Return
-99.71%
-18.1%
Beta (5-Year)
2.067
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.07
200-day SMA
Sell
Level
$0.17
Bollinger Bands (100)
Sell
Level
0.06 - 0.08
Chaikin Money Flow
Sell
Level
-162.8M
20-day SMA
Sell
Level
$0.07
Relative Strength Index (RSI14)
Buy
Level
51.19
ADX Line
Buy
Level
47.79
Williams %R
Neutral
Level
-60.3041
50-day SMA
Sell
Level
$0.07
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
99.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-246.1701)
Sell
CA Score
(Annual)
Level (-10.3261)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (27.8247)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
Stock Forecast FAQ
In the current month, HEPA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HEPA average analyst price target in the past 3 months is --.
-
Where Will Hepion Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hepion Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Hepion Pharmaceuticals, Inc.?
Analysts are divided on their view about Hepion Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hepion Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Hepion Pharmaceuticals, Inc.'s Price Target?
The price target for Hepion Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HEPA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hepion Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HEPA?
You can purchase shares of Hepion Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hepion Pharmaceuticals, Inc. shares.
-
What Is The Hepion Pharmaceuticals, Inc. Share Price Today?
Hepion Pharmaceuticals, Inc. was last trading at $0.07 per share. This represents the most recent stock quote for Hepion Pharmaceuticals, Inc.. Yesterday, Hepion Pharmaceuticals, Inc. closed at $0.07 per share.
-
How To Buy Hepion Pharmaceuticals, Inc. Stock Online?
In order to purchase Hepion Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HEPA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HEPA
Sector
P/E ratio
--
23.92x
PEG ratio
0.00x
-0.01x
P/B ratio
0.48x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
HEPA
Sector
Revenue growth
--
4.6%
Earnings growth
94.38%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.21
Profitability
HEPA
Sector
Profitability FY 2024
-$30.8K
$3.5M
Return on invested capital
-305.96%
-31.84%
Return on assets
-230.44%
-27.96%
Return on equity
-524.07%
-37.63%
Earnings Date
Last Earnings Date
Dec
28
Next Earnings Date
Dec
28
Estimated Next Earnings Date
Mar
29
Balance Sheet
HEPA
Sector
Total cash
$2.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$1.6M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
